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Abstract
Background: Alzheimer’s disease is characterized by two main neuropathological hallmarks: extracellular plaques of
amyloid-β (Aβ) protein and intracellular aggregates of tau protein. Although tau is normally a soluble monomer
that bind microtubules, in disease it forms insoluble, hyperphosphorylated aggregates in the cell body. Aside from
its role in AD, tau is also involved in several other neurodegenerative disorders collectively called tauopathies, such
as progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), some forms of frontotemporal dementia,
and argyrophilic grain disease (AGD). The prion hypothesis suggests that after an initial trigger event, misfolded
forms of tau are released into the extracellular space, where they spread through different brain regions, enter cells,
and seeding previously normal forms. Thus understanding mechanisms regulating the clearance of extracellular tau
from the CNS is important. The discovery of a true lymphatic system in the dura and its potential role in mediating
Aβ pathology prompted us to investigate its role in regulating extracellular tau clearance.
Methods: To study clearance of extracellular tau from the brain, we conjugated monomeric human tau with a
near-infrared dye cypate, and injected this labeled tau in the parenchyma of both wild-type and K14-VEGFR3-Ig
transgenic mice, which lack a functional CNS lymphatic system. Following injection we performed longitudinal
imaging using fluorescence molecular tomography (FMT) and quantified fluorescence to calculate clearance of tau
from the brain. To complement this, we also measured tau clearance to the periphery by measuring plasma tau in
both groups of mice.
Results: Our results show that a significantly higher amount of tau is retained in the brains of K14-VEGFR3-Ig vs.
wild type mice at 48 and 72 h post-injection and its subsequent clearance to the periphery is delayed. We found that
clearance of reference tracer human serum albumin (HSA) was also significantly delayed in the K14-VEGFR3-Ig mice.
Conclusions: The dural lymphatic system appears to play an important role in clearance of extracellular tau, since tau
clearance is impaired in the absence of functional lymphatics. Based on our baseline characterization of extracellular
tau clearance, future studies are warranted to look at the interaction between tau pathology and efficiency of
lymphatic function.
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Background
Alzheimer's disease (AD) is the leading cause of demen-
tia in the elderly and currently affects more than five
million people in the United States. The two main
neuropathological hallmarks of AD are extracellular pla-
ques of amyloid-β (Aβ) and intracellular accumulations
of aggregated, hyperphosphorylated forms of tau in
structures such as neurofibrillary tangles (NFT) [1]. The
amyloid cascade hypothesis holds that the triggering
event in AD pathogenesis is the initial accumulation and
aggregation of Aβ into oligomers and insoluble extracel-
lular plaques [2]. This initiates a cascade that incites the
misfolding and aggregation of soluble tau into insoluble
forms, eventually leading to neurodegeneration. Loss of
cognitive function in AD and other tauopathies is corre-
lated with the amount of aggregated tau accumulation.
In addition to its key role in AD pathology, tau has also
been implicated in a host of other neurodegenerative
disorders such as progressive supranuclear palsy (PSP),
corticobasal degeneration (CBD), certain forms of fronto-
temporal dementia (FTD) and argyrophilic grain disease
(AGD). Collectively termed tauopathies, these disorders
all feature aggregated forms of tau in the CNS [3, 4].
One model explaining part of the pathogenesis of
tauopathies is the prion hypothesis, which states that
misfolded forms of tau can exit the cell, spread to distant
regions of the brain where they can re-enter cells and
“seed” previously normal forms of the protein, much like
prion protein [5, 6]. Expression of mutant human tau in
neurons in the entorhinal cortex shows spread of tau
pathology to synaptically connected regions in the den-
tate gyrus of the hippocampus in mice [7, 8]. In addition
to seeding and uptake in cell culture [9–12], injection of
brain lysates from transgenic mice [13, 14], cell lysates
[15], synthetic recombinant tau fibrils [16, 17] and tau
extracts purified from human brains [18–22] into mouse
models have also been shown to robustly induce uptake,
seeding and spreading of tau pathology. If this model of
tau propagation is correct, it is likely that extracellular
tau plays a key role in mediating pathogenesis and
progression of tauopathy. As a result understanding the
mechanisms that regulate tau fate in the extracellular
space of the CNS and its eventual clearance to the
periphery is important.
Regulated clearance of substances out of the CNS to
the periphery is vital to healthy functioning of the CNS,
and as such is an important and active area of research.
For all the attention focused on the brain in health and
disease, little was known about fundamental clearance
mechanisms until relatively recently. For decades, it was
thought the brain enjoyed a ‘true’ immune privileged sta-
tus because of an apparent lack of lymphatic drainage
from the CNS. Early tracer injection studies showed that
peptides and solutes injected in the CSF and parenchyma
eventually make their way to deep cervical lymph nodes
(dCLNs) by traveling along olfactory sinuses and the
cribriform plates [23, 24].
More recent work, also largely done with tracers,
refined this model further by proposing that solutes are
cleared across paravascular routes and are aided in this
process by astrocytes. The role of astrocytes in mediat-
ing this clearance led to this model being called the
‘glymphatic’ (a portmanteau of glia and lymphatic)
system [25]. The water channel aquaporin 4 (AQP4),
predominantly localized to astrocytic end-feet, was
shown to be key to glymphatic clearance, as its deletion
impaired clearance of solutes to dCLNs [26–28]. This
model proposes that the interstitial fluid (ISF) compart-
ment of the brain exchanges metabolites and macromole-
cules with the CSF compartment. This is driven by arterial
pulsation [27], which causes solutes to exit the brain by
following paravascular pathways aided by AQP4.
The characterization of this system has implications
for aging and disease. Prolonged exposure to Aβ aggre-
gates has been shown to impair glymphatic function in
mouse models [29]. Deleting AQP4 leads to reduced
transport of biomarkers of neuronal injury in a mouse
model of TBI [28] and exacerbates existing tau path-
ology, presumably because tau aggregates are not cleared
out of the brain properly [30].
More recent work has upended accepted dogma by
conclusively showing that the brain does indeed have a
‘true’ lymphatic system responsible for draining macro-
molecules and cells from the deep parenchyma. These
studies demonstrated and rigorously characterized a
network of lymphatic vessels localized to the dura of the
meninges using state of the art microscopy and high
resolution fluorescent imaging [31, 32]. These dural
lymphatics were shown to track along superior sagittal
and transverse sinuses, ultimately draining into the deep
cervical lymph nodes. Ablating dural lymphatics with
either genetic manipulation or surgery resulted in sig-
nificantly slower clearance of injected macromolecules
in the deep parenchyma, perhaps indicating that the
glymphatic and lymphatic system exist in parallel and
might even be linked [32, 33]. Furthermore, it was
shown that impaired lymphatic drainage can exacerbate
amyloid pathology, particularly in the meninges [34].
Although it is known that extracellular clearance of
Aβ is regulated by the transporters at the BBB such as
RAGE, LRP1, LDLR and P-GP [35–39], by cellular
enzymes such as neprilysin [40] and insulin-degrading
enzyme [41], and by glymphatic flow [42, 43], data sur-
rounding what regulates extracellular clearance of tau is
limited. Extracellular tau in various CNS compartments
can be detected in the periphery [30, 44, 45], but it is
unclear what regulates this process. A recent study
showed that various isoforms of tau are readily detected
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in plasma following injection in the ventricles [46] but
the mechanisms mediating this process are unknown.
There is also some evidence that the glymphatic system
is involved [30]; however, the role of the dural lymphatic
system has not yet been studied. This lack of informa-
tion and proper understanding of tau clearance
prompted us to investigate the role of dural lymphatic
system in clearance of extracellular tau.
Methods
Animal surgeries and husbandry
Initial breeding pairs of K14-VEGFR3-Ig mice [47] were
obtained from Dr. Kari Alitalo at the University of
Helsinki and the colony was further expanded and main-
tained at Washington University School of Medicine. The
transgenic mice are crossed with C57/BL6 mice. WT and
TG mice used in all the experiments were littermates.
WT and K14-VEGFR3-Ig mice were anesthetized with
ketamine/xylazine cocktail before being placed in the
stereotactic surgery frame. Intrahippocampal injection of
recombinant monomeric human tau (labeled and
un-labeled) and human serum albumin (HSA) was per-
formed at the following site: bregma − 2.5 mm, lateral 2
mm from midline, 2 mm ventral to the dura. All proce-
dures were performed following protocols approved by
the Animal Studies Committee and Washington Univer-
sity School of Medicine.
Tau and HSA conjugation with cypate
Recombinant monomeric human tau (1N4R, tau-412,
rPeptide) and HSA were conjugated with near-infrared
dye cypate in the following manner: Cypate conjugation
to proteins was carried out by NHS ester chemistry [48].
Cypate-NHS was prepared by dissolving 31.3 mg (0.05
mmol) cypate in 200 μl DMSO. Next a solution of 5.8
mg (0.05 mmol) NHS, and 4.8 mg (0.025mmol) EDC
was prepared in another 200 μl DMSO solution. Finally
the two solutions were mixed and incubated overnight
at room temperature. For conjugation, 100 μg tau was
reconstituted with 90 μl pH 7.4 1 X PBS buffer. Then
0.75 μl Cypate-NHS was diluted with DMSO into 10 μl,
and then added to the 90 μl tau solution and allowed to
incubate for 2 h at room temperature.
For HSA conjugation 1.0 mg HSA was dissolved in
200 μl pH 7.4 1 X PBS buffer. Next 1.5 μl, Cypate-NHS
DMSO solution was diluted with DMSO into 20 μl,
added to the 200 μl HSA PBS solution, and then incu-
bated at room temperature for overnight. Reaction
mixtures were dialyzed with 1 X PBS, pH 7.4 at 4 °C for
overnight, and then lyophilized. Dye and protein con-
centrations were determined by protein assay (Bio-Rad)
and UV-Vis absorption spectrum, to give dye to protein
molar ratio.
In vivo FMT of tau-cypate and HSA-cypate drainage
In vivo FMT was performed on a Perkin Elmer FMT4000
imaging system. Following intra-hippocampal injection of
cypate labeled tau, mice were anesthetized with 2% isoflur-
ane for imaging. Both WTand K14-VEGFR3-Ig mice were
imaged at 1, 2, 24, 48, 72 and 168 h post-injection of tau.
A 2 μl of solution (1.1 μg) of monomeric human tau or
HSA was injected at a flow-rate of 0.2 μl/min. Fluores-
cence was quantified based on instrument calibration with
cypate phantoms. Total fluorescence of tau and HSA
fluorescent conjugates was measured in manually drawn
ROIs approximating the brain and lymph nodes. To con-
trol for variability caused by injection, data for each mouse
at each time point were normalized to the fluorescent
signal at the 1 h time point.
Plasma tau measurement
For plasma measurement, 50 mg/kg of anti-human anti-
body HJ 8.5 was injected intraperitoneally as described
in [44]. Mice were injected with 2 μl of solution (1.1 μg)
of unlabeled, monomeric tau 1 h post-antibody adminis-
tration. Blood was collected at 2, 24, 48, 72, 168 h
post-tau injection. Samples were spun at 8000 g for 10
min to obtain plasma. The Simoa HD-1 analyzer (Quan-
terix Corp) was used to measure human tau in plasma
as previously described [44].
Meningeal extraction and immunohistochemistry
Mice were anesthetized by intraperitoneal injection of
pentobarbital (200 mg/kg) for perfusion with ice-cold
Dulbecco’s PBS with Heparin. Following perfusion, the
skull cap was carefully removed and fixed overnight in
4% paraformaldehyde. Intact meninges were then peeled
off and stored as floating sections in PBS until immuno-
histochemistry. For LYVE1 staining, meninges were
washed in PBS-Triton X-100 (0.5%) and blocked in
PBS-T with 0.5% BSA at room temperature. Sections
were incubated with LYVE1-e660 (ThermoFisher) at
1:200 overnight at 40 C. Sections were washed in PBS-T
prior to mounting on slides in Prolong Gold antifade re-
agent with DAPI (ThermoFisher) mounting medium.
Slides were imaged on Zeiss Axio Imager Z2 fluores-
cence microscope and Cytation 5 imaging reader (Biotek
Imaging, Inc.). Images were processed on ZEN software
suite (Carl Zeiss, Inc.) and Cytation 5 imaging reader.
Statistics
Bulk of data plotting and statistical analysis were done
on GraphPad Prism 5. For tau-cypate (n = 6–9) and
HSA-cypate (n = 4–6) injection and brain retention stud-
ies, a two-way ANOVA with a Bonferroni post-test by
was used to analyze the two groups of mice at each time
point (i.e. 2, 24, 48, 72 and 168 h). For plasma tau
measurement a mixed effects linear model was used to
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compare plasma tau (pg/ml) for the two groups (WT n
= 5, K14-VEGFR3-Ig n = 6) across five times (2, 24, 48,
72, and 168 h). Akaike’s AIC was used to evaluate 15
ovariance structures to determine the best fit model for
the two analyses. Least square estimates of the differ-
ences between groups (i.e., mouse types or drug treat-
ment) at each time period were used to compare the
trajectory of response over time. All tests were con-
ducted at the alpha = 0.05 level of significance. All tests
were run in PROC MIXED of SAS 9.4.
Results
Extracellular tau clearance is impaired and significantly
more tau is retained in the brain of K14-VEGFR3-Ig mice
We utilized the K14-VEGFR3-Ig transgenic mice for our
studies. These mice lack a functional dural lymphatic
system [32] and thus provide a model to study the con-
tribution of this system to clearance of substances from
the brain. We first confirmed that these mice lack dural
lymphatics by immunohistochemistry for LYVE1, a
lymph endothelial cell marker (Fig. 1). WT mice show
clear distribution of lymphatic vessels along superior sa-
gittal and transverse sinuses, while K14-VEGFR3-Ig mice
have no LYVE1 staining, indicating a complete lack of
lymphatic vessels.
To assess clearance of extracellular tau from the CNS
over time, we performed serial FMT – an optical im-
aging modality that allows for in vivo imaging of fluores-
cent probes through layers of skin, bone and tissue – of
mice injected with recombinant monomeric human tau
labeled with cypate, a near-infrared dye that can be
easily conjugated to a number of different tracers,
probes and molecules for optical imaging of tumors and
other physiological processes [49–52]. In this experi-
ment, 4-6mo old WT and K14-VEGFR3-Ig mice were
imaged at 1, 2, 24, 48, 72 and 168 h post-injection of tau
(Fig. 2a). Fluorescence was quantified in the brain to cal-
culate amount of tau retained at each time point. Signal
for each mouse at each time point was normalized to
the 1 h time point. As we imaged mice over several days,
we observed a clear result: tau clearance is delayed from
the brain in K14-VEGFR3-Ig mice. Significantly more
tau is retained at 48 h (85% vs 52%) and 72 h (52% vs
22%) post-injection in the K14-VEGFR3-Ig mice,
strongly suggesting that in the absence of dural lym-
phatics, extracellular tau is not as effectively cleared
from the CNS to the periphery (Fig. 2b). This is reflected
in the half-life of tau in both groups (Fig. 2d): tau has a
shorter half-life of 39.67 h in WT mice compared to 154
h in the K14-VEGFR3-Ig mice.
Clearance of HSA from CNS is also impaired in K14-
VEGFR3-Ig mice
To get a more clear understanding of tau clearance by
lymphatics we repeated our experiment by injecting
HSA-cypate to serve as a reference tracer. Since it is
known that albumin is cleared by lymphatic vessels out
of the CNS [31, 32], we hypothesized delayed clearance
of HSA in K14-VEGFR3-Ig mice. Longitudinal FMT of 4–6
mo WT and K14-VEGFR3-Ig mice injected with
HSA-cypate reveals that significantly more HSA is retained
in the brain of the transgenic mice at 24 h (57% vs 29%)
Fig. 1 Histological characterization of the dural lymphatic system. Intact meninges from both WT and K14-VEGFR3-Ig mice were stained for
cellular marker DAPI (top) and the lymphatic endothelial marker LYVE1 (bottom). Representative sections are shown here. WT mice show the
characteristic distribution of dural lymph vessels along the superior sagittal and transverse sinuses (as delineated by LYVE1 staining). K14-VEGFR3-
Ig mice have no LYVE1 staining
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and 48 h (36% vs 15%) compared to WT mice (Fig. 2c),
suggesting that similar to tau, clearance of HSA is delayed
in mice lacking a functional dural lymphatic system. Add-
itionally we found that half-life of HSA was longer in
K14-VEGFR3-Ig mice (26 h) compared to WT mice (~ 13
h). This is in agreement with published reports of rat albu-
min’s half-life in rat brain [53, 54] being in the range of
11–18 h, thus further validating this method to measuring
CNS clearance of proteins. The fact that HSA is cleared
faster than tau could perhaps indicate uptake and/or
additional extracellular retention of tau within CNS.
Measurement of plasma tau reveals a trend toward
delayed clearance in K14-VEGFR3-Ig mice
As we showed there is delayed clearance of extracellular





Fig. 2 K14-VEGFR3-Ig mice retain significantly more tau in the brain following intra-CNS injection. a Panel showing distribution and gradual
clearance of tau-cypate (as measured by longitudinal FMT) in a representative WT mouse from pre-injection through 168 h post-injection.
Monomeric recombinant human tau was conjugated with the near-infrared fluorescent dye cypate and stereotactically injected in the
hippocampus of WT and K14-VEGFR3-Ig mice. Mice were longitudinally imaged with FMT at the time-points indicated. The same injection and
imaging timeline was followed for experiments involving clearance of HSA-cypate in WT and K14-VEGFR3-Ig mice b Significantly more tau is
retained in the brain of K14-VEGFR3-Ig mice, indicating delayed clearance. 4–6 mo old WT (n = 9; 5 males, 4 females) and K14-VEGFR3-Ig mice (n
= 6; 3 males, 3 females) were injected with tau-cypate in the hippocampus. They were imaged with FMT at 1, 2, 24, 48, 72 and 168 h post
injection. The amount of fluorescence in the brain was quantified and normalized to values for the 1 h time point. A significantly higher amount
of tau was retained in the K14-VEGFR3-Ig mice compared to WT mice at 48 h (85% vs 52% retention) and 72 h (52% vs 22% retention), following
injection. Data was analyzed by a two-way ANOVA with a Bonferroni post-test. (** p-value < 0.01). c Significantly more HSA is retained in the
brain of K14-VEGFR3-Ig mice, indicating delayed clearance. 4–6 mo old WT (n = 4; 1 male, 3 females) and K14-VEGFR3-Ig mice (n = 6; 4 males, 2
females) were injected with HSA-cypate in the hippocampus. They were imaged with FMT at 1, 2, 24, 48, 72 and 168 h post injection. The
amount of fluorescence in the brain was quantified and normalized to values for the 1 h time point. A significantly higher amount of HSA was
retained in the K14-VEGFR3-Ig mice compared to WT mice at 24 h (57% vs 29% retention) and 48 h (36% vs 15% retention) following injection.
Data was analyzed by a two-way ANOVA with a Bonferroni post-test. (** p-value < 0.01, * p-value < 0.05). d Table summarizing half-life of tau and
HSA in the CNS following their injection in both WT and K14-VEGFR3-Ig mice. The half-life of both proteins is longer in the K14-VEGFR3-Ig mice
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of tau appearing in the blood would also be delayed. In
order to study this directly, we measured plasma tau in
both groups of mice to complement FMT experiments
looking at brain retention of tau to get a more complete
picture of tau clearance. We used an antibody-mediated
approach [44] to increase half-life of soluble tau in the
plasma to allow us to measure it reliably. This was done
because the half-life of tau once it reaches the plasma is
only 8.49 min; however, in the presence of the anti-tau
antibody HJ8.5, the half-life of plasma tau increases to
3.4 h allowing one to measure it there in a more facile
fashion [44]. Following intraperitoneal antibody adminis-
tration of HJ 8.5 (an anti-human tau antibody), WT and
K14-VEGFR3-Ig mice were injected in the hippocampus
with 1.1 μg tau. Blood was collected at 2, 24, 48, 72 and
168 h post-injection and plasma human tau was mea-
sured by a high-sensitivity ELISA on a Simoa analyzer.
The plasma tau assay uses capture antibody HJ8.7
(which binds to N-terminal epitopes 117–122 of tau)
and biotinylated detection antibody BT2 (which binds to
epitopes 194–198 of tau). We found that K14-VEGFR3-
Ig mice, which retained a significantly higher amount of
tau in the brain, correspondingly also show delayed
appearance of tau in the periphery (Fig. 3) compared to
WT mice. The amount of human tau in the plasma
peaked earlier in the WT mice than in the K14-VEG-
FR3-Ig mice (24 h vs. 48 h). Significantly higher plasma
tau was present in K14-VEGFR3-Ig mice at 48 h, when
the WT mice had already cleared most of the tau from
the periphery. Together with the fluorescence data from
the brain, these plasma tau measurements strongly sug-
gest that impaired dural lymphatic function leads to in-
creased retention in the brain as well as delayed
clearance of tau to the periphery.
Discussion
While intracellular forms of tau are critical for its nor-
mal function as well as its role in neurodegenerative dis-
eases, extracellular forms of tau appear to have an
important role in the process of tau aggregate spreading
transynaptically in different tauopathies as well as
possibly in a component of tau toxicity. Given this, it is
important to understand what regulates the clearance of
extracellular tau from the brain. One important recently
identified pathway that is involved in extracellular pro-
tein clearance from the brain is the dural lymphatics. Be-
cause of the recent discovery of bona fide lymph vessels
in the meninges, we particularly focused on their role in
this process. By using the K14-VEGFR3-Ig mouse model,
which lacks dural lymphatics and shows delayed clear-
ance of CNS macromolecules and tracers [32], we dem-
onstrated that extracellular tau clearance from the CNS
is significantly impaired in the absence of a functioning
dural lymphatic system. A significantly higher amount of
tau is retained in the brain of the K14-VEGFR3-Ig mice
and its eventual clearance and appearance in the periph-
ery is also delayed.
As our work was done to establish ‘baseline’ clearance
mechanism of monomeric tau, it opens several exciting
future directions: does disruption of lymphatic vessels
Fig. 3 K14-VEGFR3-Ig mice show delayed clearance of extracellular tau to the plasma after intra CNS injection. 4-6mo old WT (n = 6; 3 males, 3
females) and K14-VEGFR3-Ig mice (n = 5; 3 males, 2 females) were injected with anti-tau antibody HJ 8.5 to stabilize tau entering the plasma from
the CNS to allow for its measurement. An hour later recombinant monomeric human tau was injected in the hippocampus and blood was
collected at time points indicated. Plasma tau was measured using the ultrasensitive Simoa HD1-Analyzer platform. Though the overall difference
between tau for the two mouse groups was not significant (p = 0.6766), the interaction between the two mouse groups over time was significant
(p = 0.0191). Plasma tau peaks earlier in WT mice compared to K14-VEGFR3-Ig mice (24 vs 48 h). Amount of plasma tau is significantly higher in
K14-VEGFR3-Ig mice at 48 h compared to WT mice (p = 0.0260), indicative of delayed clearance of tau due to impaired lymphatics. Data was
analyzed by mixed effects linear model. Akaike’s AIC was used to evaluate 15 covariance structures to determine the best fit model for this
analysis. Least square estimates of the differences between the two mouse groups at each time period were used to compare the trajectory of
response over time
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exacerbate tau pathology? What effect does age have on
lymphatic clearance of tau? Is clearance of aggregated
tau markedly different than monomeric tau? The mice
we used in our work are otherwise healthy and do not
show any neuropathological alterations (such as tau ag-
gregation). As a result it would be interesting to deter-
mine whether the clearance of tau is altered in the
presence of significant AD or other pathology as this will
help us to understand if there is a link between CNS
lymphatics and neurodegeneration.
Since the glymphatic system appears to play a key role
in the ISF-CSF exchange of solutes, we can propose a
model of extracellular tau clearance that traces the fate
of ISF tau: following its release into the ISF compart-
ment, tau is cleared into the CSF space by the glympha-
tic system. Once in the CSF it is drained to the cervical
lymph nodes by the dural lymphatic system. Thus the
glymphatic and lymphatic systems most likely work in
tandem to accomplish the eventual clearance of tau to
the periphery.
However one key observation from our FMT exper-
iments in K14-VEGFR3-Ig mice is that despite
complete lack of lymphatic vessels, extracellular tau is
still able to be cleared out of the brain to the periph-
ery, albeit at a much slower rate than in healthy WT
mice. This implies the existence of alternate paths for
tau clearance and/or uptake within the CNS. Coupled
with the fact that passive clearance of HSA appears
to be faster than passive clearance of tau (despite
their similar molecular weights) this leads to the hy-
pothesis that the dural lymphatic system might show
some specificity in transporting macromolecules out
of the CNS. The potential existence of alternate clearance
mechanisms needs to be investigated further. K14-VEG-
FR3-Ig mice lack a functional lymphatic system owing to
lack of signaling through the VEGFR3 receptor. Mice
show complete lack of lymph vasculature and profound
lymphedema. They survive the neonatal period despite
these defects and subsequently even show regeneration of
lymph vasculature in the periphery. In adulthood they
only lack the dural lymphatic system [32, 47]. Though
these mice do not have any defects in vascular permeabil-
ity that are detectable, it is possible that abnormal devel-
opment of peripheral lymphatics might also lead to
disturbance in degradation and eventual clearance of
plasma tau.
Finally, in the process of investigating the contribution
of dural lymphatics to extracellular clearance we made
extensive use of FMT, a technique that has previously
been used mostly to study tumor evolution and other
related cellular processes in vivo [49]. We have thus
established a novel use for this versatile technique,
which can hopefully be used for more extensive clear-
ance studies in the future.
Conclusions
We demonstrate a novel use of FMT in studying clearance
of extracellular tau from the CNS. Using a mouse model
lacking functional lymphatics we performed longitudinal
FMT to show that tau clearance is notably impaired in the
absence of functional lymphatics and its eventual clear-
ance to the periphery is significantly delayed, thus estab-
lishing a key role for the dural lymphatic system in
mediating extracellular tau clearance. Our study highlights
a likely link between the glymphatic and lymphatic
systems in mediating extracellular clearance and opens
new avenues to investigate the interplay between neurode-
generation and the dural lymphatic system.
Abbreviations
AD: Alzheimer's disease; AGD: Argyrophillic grain disease; AQP4: Aquaporin 4;
Aβ: Amyloid beta; BBB: Blood brain barrier; CBD: Corticobasal degeneration;
CNS: Central nervous system; CSF: Cerebrospinal fluid; dCLN: Deep cervical
lymph node; FMT: Fluorescence molecular tomography; FTD: Frontotemporal
dementia; HSA: Human serum albumin; ISF: Interstitial fluid; LDLR: Low
density lipoprotein recetor; LRP1: Low density lipoprotein receptor-related
protein 1; NFT: Neurofibrillary tangle; P-GP: P-glycoprotein; PSP: Progressive
supranuclear palsy; RAGE: Receptor for advanced glycation end products;
WT: Wild-type
Acknowledgements
We would like to thank Jason D. Ulrich and Mary Beth Finn at Washington
University School of Medicine for discussions and valuable technical input at
various times in the project.
Funding
This work was supported by NIH R01 NS090934, AG04867801, the Tau
Consortium and the JPB Foundation to DMH and 1S10OD020129 (SA).
Availability of data and materials
The datasets used and/or analyzed during the current study are available
from the corresponding author on reasonable request.
Authors’ contributions
TKP and DMH conceived and designed the study with critical input from
LHG. TKP and DMH wrote, and ESM and SA assisted with editing the
manuscript with input from all co-authors. TKP performed stereotactic surgeries,
plasma collection, Simoa assays, immunohistochemistry, image analysis.
LHG, XG, BX performed protein conjugation. TKP and LHG performed
FMT experiments. LHG performed FMT image analysis. KA graciously provided
K14-VEGFR3-Ig mice for the study and provided supporting data. CAM
and TKP performed meningeal extraction. PWS and TKP performed imaging of
meningeal sections. CX and DC performed additional statistical analysis. All
authors read and approved the final manuscript.
Ethics approval and consent to participate
Animal husbandry, housing and all procedures were performed following
protocols approved by the Animal Studies Committee and Washington




DMH is listed as an inventor on a patent licensed by Washington University
to C2N Diagnostics on the therapeutic use of anti-tau antibodies. DMH co-
founded and is on the scientific advisory board of C2N Diagnostics, LLC. C2N
Diagnostics, LLC has licensed certain anti-tau antibodies to AbbVie for
therapeutic development. DMH is on the scientific advisory board of
Proclara and Denali and consults for Genentech and AbbVie.
Patel et al. Molecular Neurodegeneration           (2019) 14:11 Page 7 of 9
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Neurology, Hope Center for Neurological Disorders, Knight
Alzheimer’s Disease Research Center, Washington University in St. Louis, St.
Louis, MO 63110, USA. 2Department of Radiology, Washington University, St.
Louis, MO 63110, USA. 3Department of Biochemistry and Molecular
Biophysics, Department of Biomedical Engineering, Washington University, St.
Louis, MO 63110, USA. 4Wihuri Research Institute and Translational Cancer
Biology Program, Biomedicum Helsinki, University of Helsinki, Helsinki,
Finland. 5Division of Biostatistics, Knight Alzheimer’s Disease Research Center,
Washington University, St. Louis, MO 63110, USA.
Received: 26 November 2018 Accepted: 20 February 2019
References
1. Holtzman DM, Mandelkow E, Selkoe DJ. Alzheimer Disease in 2020. Cold
Spring Harb Perspect Med. 2012;2(11):a011585.
2. Musiek ES, Holtzman DM. Three dimensions of the amyloid hypothesis:
time, space and “wingmen”. Nat Neurosci. 2015;18(6):800–6.
3. Mandelkow EM, Mandelkow E. Biochemistry and cell biology of tau
protein in neurofibrillary degeneration. Cold Spring Harb Perspect Biol.
2012;4(6):1–25.
4. Li C, Götz J. Tau-based therapies in neurodegeneration: opportunities and
challenges. Nat Rev Drug Discov. 2017;16(12):863–83.
5. Jucker M, Walker LC. Self-propagation of pathogenic protein aggregates in
neurodegenerative diseases. Nature. 2013;501(7465):45–51.
6. Davis AA, Leyns CEG, Holtzman DM. Intercellular spread of protein
aggregates in neurodegenerative disease. Annu Rev Cell Dev Biol. 2018;
34(1):545–68.
7. de Calignon A, Polydoro M, Suárez-Calvet M, William C, Adamowicz DH,
Kopeikina KJ, et al. Propagation of tau pathology in a model of early
Alzheimer’s disease. Neuron. 2012;73(4):685–97.
8. Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, et al. Trans-synaptic
spread of tau pathology in vivo. PLoS One. 2012;7(2):e31302.
9. Holmes BB, Furman JL, Mahan TE, Yamasaki TR, Mirbaha H, Eades WC, et al.
Proteopathic tau seeding predicts tauopathy in vivo. Proc Natl Acad Sci.
2014;111(41):E4376–85.
10. Kfoury N, Holmes BB, Jiang H, Holtzman DM, Diamond MI. Trans-cellular
propagation of tau aggregation by fibrillar species. J Biol Chem. 2012;
287(23):19440–51.
11. Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the
outside to the inside of a cell. J Biol Chem. 2009;284(19):12845–52.
12. Wu JW, Herman M, Liu L, Simoes S, Acker CM, Figueroa H, et al. Small
misfolded tau species are internalized via bulk endocytosis and
Anterogradely and Retrogradely transported in neurons. J Biol Chem. 2013;
288(3):1856–70.
13. Ahmed Z, Cooper J, Murray TK, Garn K, McNaughton E, Clarke H, et al. A
novel in vivo model of tau propagation with rapid and progressive
neurofibrillary tangle pathology: the pattern of spread is determined by
connectivity, not proximity. Acta Neuropathol. 2014;127(5):667–83.
14. Clavaguera F, Hench J, Lavenir I, Schweighauser G, Frank S, Goedert M, et al.
Peripheral administration of tau aggregates triggers intracerebral tauopathy
in transgenic mice. Acta Neuropathol. 2014;127(2):299–301.
15. Sanders DW, Kaufman SK, DeVos SL, Sharma AM, Mirbaha H, Li A, et al.
Distinct tau prion strains propagate in cells and mice and define different
Tauopathies. Neuron. 2014;82(6):1271–88.
16. Iba M, Guo JL, McBride JD, Zhang B, Trojanowski JQ, Lee VM-Y. Synthetic
tau fibrils mediate transmission of neurofibrillary tangles in a transgenic
mouse model of Alzheimer’s-like tauopathy. J Neurosci. 2013;33(3):1024–37.
17. Peeraer E, Bottelbergs A, Van Kolen K, Stancu I-C, Vasconcelos B, Mahieu M,
et al. Intracerebral injection of preformed synthetic tau fibrils initiates
widespread tauopathy and neuronal loss in the brains of tau transgenic
mice. Neurobiol Dis. 2015;73:83–95.
18. Clavaguera F, Akatsu H, Fraser G, Crowther RA, Frank S, Hench J, et al. Brain
homogenates from human tauopathies induce tau inclusions in mouse
brain. Proc Natl Acad Sci U S A. 2013;110(23):9535–40.
19. Boluda S, Iba M, Zhang B, Raible KM, Lee VM-Y, Trojanowski JQ. Differential
induction and spread of tau pathology in young PS19 tau transgenic mice
following intracerebral injections of pathological tau from Alzheimer’s
disease or corticobasal degeneration brains. Acta Neuropathol. 2014;
129(2):221–37.
20. He Z, Guo JL, McBride JD, Narasimhan S, Kim H, Changolkar L, et al.
Amyloid-β plaques enhance Alzheimer’s brain tau-seeded pathologies by
facilitating neuritic plaque tau aggregation. Nat Med. 2018;24(1):29–38.
21. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ,
Kiritoshi T, Neugebauer V, et al. Alzheimer brain-derived tau oligomers
propagate pathology from endogenous tau. Sci Rep. 2012;2(1):700.
22. Guo JL, Narasimhan S, Changolkar L, He Z, Stieber A, Zhang B, et al. Unique
pathological tau conformers from Alzheimer’s brains transmit tau pathology
in nontransgenic mice. J Exp Med. 2016;213(12):2635–54.
23. Cserr HF, Harling-Berg CJ, Knopf PM. Drainage of brain extracellular fluid
into blood and deep cervical lymph and its immunological significance.
Brain Pathol. 1992;2(4):269–76.
24. Rennels ML, Gregory TF, Blaumanis OR, Fujimoto K, Grady PA. Evidence for a
‘Paravascular’ fluid circulation in the mammalian central nervous system,
provided by the rapid distribution of tracer protein throughout the brain
from the subarachnoid space. Brain Res. 1985;326(1):47–63.
25. Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Thiyagarajan M, et al. Sleep drives
metabolite clearance from the adult brain. Science. 2013;342(6156):373–7.
26. Iliff JJ, Lee H, Yu M, Feng T, Logan J, Nedergaard M, et al. Brain-wide
pathway for waste clearance captured by contrast-enhanced MRI. J Clin
Invest. 2013;123(3):1299–309.
27. Iliff JJ, Wang M, Zeppenfeld DM, Venkataraman A, Plog BA, Liao Y, et al.
Cerebral arterial pulsation drives Paravascular CSF-interstitial fluid exchange
in the murine brain. J Neurosci. 2013;33(46):18190–9.
28. Plog BA, Dashnaw ML, Hitomi E, Peng W, Liao Y, Lou N, et al. Biomarkers of
traumatic injury are transported from brain to blood via the Glymphatic
system. J Neurosci. 2015;35(2):518–26.
29. Peng W, Achariyar TM, Li B, Liao Y, Mestre H, Hitomi E, et al. Suppression of
glymphatic fluid transport in a mouse model of Alzheimer’s disease.
Neurobiol Dis. 2016;93:215–25.
30. Iliff JJ, Chen MJ, Plog BA, Zeppenfeld DM, Soltero M, Yang L, et al.
Impairment of Glymphatic pathway function promotes tau pathology after
traumatic brain injury. J Neurosci. 2014;34(49):16180–93.
31. Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, et al.
Structural and functional features of central nervous system lymphatic
vessels. Nature. 2015;523(7560):337–41.
32. Aspelund A, Antila S, Proulx ST, Karlsen TV, Karaman S, Detmar M, et al. A
dural lymphatic vascular system that drains brain interstitial fluid and
macromolecules. J Exp Med. 2015;212(7):991–9.
33. Louveau A, Plog BA, Antila S, Alitalo K, Nedergaard M, Kipnis J.
Understanding the functions and relationships of the glymphatic system
and meningeal lymphatics. J Clin Invest. 2017;127(9):3210–9.
34. Da Mesquita S, Louveau A, Vaccari A, Smirnov I, Cornelison RC, Kingsmore
KM, et al. Functional aspects of meningeal lymphatics in ageing and
Alzheimer’s disease. Nature. 2018;560(7717):185–91.
35. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, et al.
RAGE mediates amyloid-β peptide transport across the blood-brain barrier
and accumulation in brain. Nat Med. 2003;9(7):907–13.
36. Castellano JM, Deane R, Gottesdiener AJ, Verghese PB, Stewart FR, West T,
et al. Low-density lipoprotein receptor overexpression enhances the rate of
brain-to-blood a clearance in a mouse model of -amyloidosis. Proc Natl
Acad Sci. 2012;109(38):15502–7.
37. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, et al.
Clearance of Alzheimer’s amyloid-β1-40 peptide from brain by LDL
receptor–related protein-1 at the blood-brain barrier. J Clin Invest. 2000;
106(12):1489–99.
38. Elali A, Rivest S. The role of ABCB1 and ABCA1 in beta-amyloid clearance at
the neurovascular unit in Alzheimer’s disease. Front Physiol. 2013;4:45.
39. Tarasoff-Conway JM, Carare RO, Osorio RS, Glodzik L, Butler T, Fieremans E,
et al. Clearance systems in the brain—implications for Alzheimer disease.
Nat Rev Neurol. 2015;11(8):457–70.
40. Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, et al. Metabolic
regulation of brain Abeta by neprilysin. Science. 2001;292(5521):1550–2.
41. Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB, et al. Insulin-
degrading enzyme regulates extracellular levels of amyloid beta-protein by
degradation. J Biol Chem. 1998;273(49):32730–8.
Patel et al. Molecular Neurodegeneration           (2019) 14:11 Page 8 of 9
42. Iliff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA, et al. A
Paravascular pathway facilitates CSF flow through the brain parenchyma
and the clearance of interstitial solutes, including amyloid. Sci Transl Med.
2012;4(147):147ra111.
43. Kress BT, Iliff JJ, Xia M, Wang M, Wei HS, Zeppenfeld D, et al.
Impairment of paravascular clearance pathways in the aging brain. Ann
Neurol. 2014;76(6):845–61.
44. Yanamandra K, Patel TK, Jiang H, Schindler S, Ulrich JD, Boxer AL, et al. Anti-
tau antibody administration increases plasma tau in transgenic mice and
patients with tauopathy. Sci Transl Med. 2017;9(386):eaal2029.
45. Shahim P, Tegner Y, Wilson DH, Randall J, Skillbäck T, Pazooki D, et al. Blood
biomarkers for brain injury in concussed professional ice hockey players.
JAMA Neurol. 2014;71(6):684–92.
46. Banks WA, Kovac A, Majerova P, Bullock KM, Shi M, Zhang J. Tau proteins
cross the blood-brain barrier. J Alzheimers Dis. 2016;55(1):411–9.
47. Mäkinen T, Jussila L, Veikkola T, Karpanen T, Kettunen MI, Pulkkanen KJ, et al.
Inhibition of lymphangiogenesis with resulting lymphedema in transgenic
mice expressing soluble VEGF receptor-3. Nat Med. 2001;7(2):199–205.
48. Nanda JS, Lorsch JR. Labeling of a protein with fluorophores using
maleimide derivitization. Methods Enzymol. 2014;536:79–86.
49. Zhang X, Bloch S, Akers W, Achilefu S. Near-Infrared Molecular Probes for In
Vivo Imaging. Curr Protoc Cytom. 2012;Chapter 12:Unit12.27.
50. Achilefu S, Dorshow RB, Bugaj JE, Rajagopalan R. Novel receptor-targeted
fluorescent contrast agents for in vivo tumor imaging. Investig Radiol. 2000;
35(8):479–85.
51. Ye Y, Li WP, Anderson CJ, Kao J, Nikiforovich GV, Achilefu S. Synthesis and
characterization of a macrocyclic near-infrared optical scaffold. J Am Chem
Soc. 2003;125(26):7766–7.
52. Ye Y, Bloch S, Kao J, Achilefu S. Multivalent carbocyanine molecular probes:
synthesis and applications. Bioconjug Chem. 2005;16(1):51–61.
53. Cserr HF, Cooper DN, Suri PK, Patlak CS. Efflux of radiolabeled
polyethylene glycols and albumin from rat brain. Am J Physiol Physiol.
1981;240(4):F319–28.
54. Yamada S, DePasquale M, Patlak CS, Cserr HF. Albumin outflow into deep
cervical lymph from different regions of rabbit brain. Am J Physiol Circ
Physiol. 1991;261(4):H1197–204.
Patel et al. Molecular Neurodegeneration           (2019) 14:11 Page 9 of 9
